

---

**REMARKS**

---

This paper is responsive to an Office Action dated May 25, 2005. Prior to this response claims 1-38 were pending. After amending claims 1, 6, 20, 30-31, 33, and 37, and canceling claims 3-5, 19, and 22-29, claims 1-2, 6-18, 20-21, and 30-38 remain pending.

In Section 2 of the Office Action, claims 1-18, 20-28, and 31-38 have been rejected as anticipated under 35 U.S.C. 102(b) with respect to Balakrishnan (US 5,566,208).

Section 3 of the Office Action states that claims 19 and 29-30 would be found allowable if rewritten in independent form, including all the subject matter of the base and intervening claims. In response, claim 1 has been amended to include the subject matter of claims 3-5 and 19 (now canceled). All claims dependent from claim 1 should be found allowable. Likewise, claim 20 has been amended to include the subject matter of claims 22-29 (now canceled). All claims dependent from claim 20 should be allowable.

---

**BEST AVAILABLE COPY**

It is believed that the application is in condition for  
~~allowance and reconsideration is earnestly solicited.~~

Date: 5/17/05

Respectfully submitted,

  
David Ripma  
Registration No. 27,672

Customer Number 27518  
David Ripma, Patent Counsel  
Sharp Laboratories of America, Inc.  
5750 NW Pacific Rim Blvd.  
Camas, WA 98607  
Telephone: (360) 834-8754  
Facsimile: (360) 817-8505

**BEST AVAILABLE COPY**